Irinotecan
- Generic Name
- Irinotecan
- Brand Names
- Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
- Drug Type
- Small Molecule
- Chemical Formula
- C33H38N4O6
- CAS Number
- 97682-44-5
- Unique Ingredient Identifier
- 7673326042
- Background
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothe...
- Indication
For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluo...
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
- Associated Therapies
- -
Phase I Study of PN401, Fluorouracil, Leucovorin and CPT-11 in Patients With Solid Tumors
- Conditions
- First Posted Date
- 2002-09-06
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Wellstat Therapeutics
- Target Recruit Count
- 24
- Registration Number
- NCT00044785
- Locations
- 🇺🇸
University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland, United States
A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer
- Conditions
- First Posted Date
- 2002-06-27
- Last Posted Date
- 2016-12-01
- Lead Sponsor
- Celgene Corporation
- Registration Number
- NCT00040391
- Locations
- 🇺🇸
Research Center, Milwaukee, Wisconsin, United States
Irinotecan in Treating Patients With Refractory Solid Tumors and Liver Dysfunction
- Conditions
- First Posted Date
- 2002-05-22
- Last Posted Date
- 2009-08-14
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00037804
- Locations
- 🇺🇸
Research Center, Marshfield, Wisconsin, United States
For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy
- Conditions
- First Posted Date
- 2002-05-17
- Last Posted Date
- 2008-09-29
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 212
- Registration Number
- NCT00037180
- Locations
- 🇺🇸
Pfizer Investigational Site, Milwaukee, Wisconsin, United States
A Trial of ALIMTA (Pemetrexed) Plus Irinotecan in Patients Who Have Been Previously Treated For Metastatic Colorectal Cancer.
- Conditions
- First Posted Date
- 2002-04-30
- Last Posted Date
- 2006-07-19
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT00034502
- Locations
- 🇩🇪
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician., Munchen, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.